Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatoprotective role for ERMP1 in MASLD-driven hepatocarcinogenesis and β-catenin-mutated tumors.

Cancer letters - 1 Jun 2026

Gjorgjieva Monika, Correia de Sousa Marta, Delangre Etienne, Abegg Daniel, Maeder Christine, Fournier Margot, Morin Noëlie, Adibekian Alexander, Serra Fulvia, Sempoux Christine, Maechler Pierre, Foti Michelangelo

Abstract excerpt

Metabolic dysfunction-associated steatotic liver disease (MASLD) ranges from simple steatosis to steatohepatitis and fibrosis, with cirrhosis and hepatocellular carcinoma (HCC) as end-stage complications. Beyond gene mutations, altered expression of metabolism-related genes contributes to MASLD progression toward HCC. We identified the poorly characterized endoplasmic reticulum metallopeptidase 1 (ERMP1) as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Hepatocellular

Share to Disease Progression

Share to Fatty Liver

Share to Gene Expression Regulation, Neoplastic

Share to Liver Neoplasms

Share to Mice, Knockout

Source

Identifiers

PMID: 41825847
DOI: 10.1016/j.canlet.2026.218427

Genes

ERMP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatoprotective role for ERMP1 in MASLD-driven hepatocarcinogenesis and β-catenin-mutated tumors.PMID 41825847Read ↗

Aspartame Drives the Continuous Progression from MASLD to HCC: An Integrated AnalysisSemantic proximity Read ↗

MTARC1 Regulates Lipid Droplet Degradation via Phospholipid Remodeling in Metabolic Fatty Liver DiseaseSemantic proximity Read ↗

Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune AnalysisSemantic proximity Read ↗

BAP1 modulates endoplasmic reticulum stress signaling and balances liver homeostasis and malignant progressionSemantic proximity Read ↗

Genomic and transcriptomic analyses of chemical hepatocarcinogenesis aggravated by oncoprotein lossSemantic proximity Read ↗

Hepatocyte MLKL Drives Obesity-Driven Hepatocellular Carcinoma Progression via Mitochondrial Dysfunction Independent of Necroptosis in MASLDSemantic proximity Read ↗

Identification of Downregulated Exosome-Associated Gene ENPP1 as a Novel Lipid Metabolism and Immune-Associated Biomarker for Hepatocellular CarcinomaSemantic proximity Read ↗

Loss of mitochondrial amidoxime-reducing component 1 (mARC1) prevents disease progression by reducing fibrosis in multiple mouse models of chronic liver diseaseSemantic proximity Read ↗

Amplification of Glyceronephosphate O-Acyltransferase and Recruitment of USP30 Stabilize DRP1 to Promote Hepatocarcinogenesis.Semantic proximity Read ↗

Evaluation of MARC1 Variants and Extracellular Vesicle Cytokeratin-18 as Predictive Biomarkers in a group of Egyptian MASLD and MASH patientsSemantic proximity Read ↗

Hepatocyte‐Targeted Lipid Nanoparticle Delivery of HERC2 Plasmid Controls Drug‐Induced Hepatotoxicity by Limiting β‐Catenin‐Regulated CYP2E1 ExpressionSemantic proximity Read ↗

The role of MDM2–p53 axis dysfunction in the hepatocellular carcinoma transformationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.